title: Endocavitary irradiation for early rectal carcinomas T1 (T2). A series of 101 patients treated with the Papillon's technique.
abstract: OBJECTIVE
  This work is a retrospective analysis of a series of patients treated with endocavitary irradiation stressing the role of transrectal ultrasound (TRUS), which has been used routinely in the staging since 1987.
  
  
  METHODS
  Between 1977 and 1993, 101 patients with infiltrating adenocarcinomas were treated. Clinical staging was 65 T1 N0 and 36 T2 N0. TRUS used in 36 patients showed: 22 UT1 N0, 10 UT2 N0, and 3 UT2 N1. Contact x-ray was delivered with a 50 kV radiotherapy unit. The median dose was 92 Gy (60-125) in five fractions, 55 days. In 28 patients a boost was given with 192Ir implant delivering a median dose of 25 Gy/21 h.
  
  
  RESULTS
  Complete response was observed in all patients at the completion of treatment. Loco-regional failures were seen in 14 patients (local in 7 patients, nodal pararectal in 6 patients, and local + nodal in 1 patient). A curative salvage treatment was attempted in 13 patients and resulted in an ultimate pelvic control rate of 99 patients. Rectal preservation was possible in 92 patients. Overall and specific 5-year survival was 83.3% and 94.4%. No serious complication was observed. TRUS was more sensitive than digital rectal examination to detect involvement of pararectal metastatic nodes (N1). No loco- regional relapse was observed out of 22 UT1 N0.
  
  
  CONCLUSIONS
  Endocavitary irradiation can cure early adenocarcinoma of the rectum without complication. TRUS appears as a significant improvement in the selection of patients amenable to this treatment. If restricted to UT1 N0 tumors, endocavitary irradiation should control locally more than 90% of these patients. Any UN1 is a contraindication for endocavitary irradiation alone.
authors.affiliation: Service de Radiothérapie-Oncologie, Hospices Civils de Lyon, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Gérard
authors.forename: L
authors.initials: L
authors.lastname: Ayzac
authors.forename: R
authors.initials: R
authors.lastname: Coquard
authors.forename: P
authors.initials: P
authors.lastname: Romestaing
authors.forename: J M
authors.initials: JM
authors.lastname: Ardiet
authors.forename: F P
authors.initials: FP
authors.lastname: Rocher
authors.forename: N
authors.initials: N
authors.lastname: Barbet
authors.forename: J L
authors.initials: JL
authors.lastname: Cenni
authors.forename: J C
authors.initials: JC
authors.lastname: Souquet
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D012004:Rectal Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D012007:Rectum; D012189:Retrospective Studies; D016019:Survival Analysis; D017211:Treatment Failure; D014463:Ultrasonography
chemical_list: D007496:Iridium Radioisotopes